These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30019118)

  • 21. The healthcare costs of treating human papillomavirus-related cancers in Norway.
    Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
    BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
    Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
    Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
    Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data.
    Ali H; Donovan B; Wand H; Read TR; Regan DG; Grulich AE; Fairley CK; Guy RJ
    BMJ; 2013 Apr; 346():f2032. PubMed ID: 23599298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme.
    Chow EP; Read TR; Wigan R; Donovan B; Chen MY; Bradshaw CS; Fairley CK
    Sex Transm Infect; 2015 May; 91(3):214-9. PubMed ID: 25305210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
    Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015.
    Park YJ; Kim JM; Lee BR; Kim TH; Lee EG
    Epidemiol Infect; 2018 Jan; 146(2):177-186. PubMed ID: 29235433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data.
    Ali H; McManus H; O'Connor CC; Callander D; Kong M; Graham S; Saulo D; Fairley CK; Regan DG; Grulich A; Low N; Guy RJ; Donovan B
    Med J Aust; 2017 Mar; 206(5):204-209. PubMed ID: 28301790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.
    Oliphant J; Perkins N
    N Z Med J; 2011 Jul; 124(1339):51-8. PubMed ID: 21952330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The health and economic burden of genital warts in a set of private health plans in the United States.
    Insinga RP; Dasbach EJ; Myers ER
    Clin Infect Dis; 2003 Jun; 36(11):1397-403. PubMed ID: 12766834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study.
    Coskuner ER; Ozkan TA; Karakose A; Dillioglugil O; Cevik I
    J Sex Med; 2014 Nov; 11(11):2785-91. PubMed ID: 25124237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology of genital warts in the British population: implications for HPV vaccination programmes.
    Sonnenberg P; Tanton C; Mesher D; King E; Beddows S; Field N; Mercer CH; Soldan K; Johnson AM
    Sex Transm Infect; 2019 Aug; 95(5):386-390. PubMed ID: 30723185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
    Thomas TL
    Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas.
    Lairson DR; Fu S; Chan W; Xu L; Shelal Z; Ramondetta L
    Gynecol Oncol; 2017 Apr; 145(1):108-113. PubMed ID: 28196673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What can surveillance of genital warts tell us?
    Fairley CK; Donovan B
    Sex Health; 2010 Sep; 7(3):325-7. PubMed ID: 20719222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.
    Perkins RB; Lin M; Wallington SF; Hanchate A
    Sex Transm Dis; 2017 Jun; 44(6):365-370. PubMed ID: 28499288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.